PCSK9 and hyperlipidemia: Release of ICAM-1 from vascular endothelial cells was reduced with PCSK9i alirocumab and anti-PCSK9 vaccine AT04 in the APOE∗3Leiden.CETP transgenic mouse model for hyperlipidemia and atherosclerosis [40, 41].